Qura, Inc. has developed the QSmart™ System, a wireless, implantable pressure sensor and monitoring system designed to continuously detect and track intraocular pressure (IOP). The micro-sized, programmable sensor collects continuous IOP data and delivers it to desktop, handheld or tablet devices so physicians can evaluate treatment effectiveness in real time. Qura positions the system to facilitate timely and targeted medical or surgical intervention for glaucoma patients worldwide, noting approximately 80 million people are affected by glaucoma. The company announced a $1 million strategic investment from Santen Ventures to support development and commercialization as part of its Series A financing. The QSmart™ System is currently in the pre-clinical stage of development. InFocus Capital Partners initiated and sponsored the Series A round. Qura Inc. develops QSmart, a wireless implantable pressure sensor technology and monitoring system aimed at improving medical and surgical management of glaucoma. QSmart is a micro-sized, wireless implantable sensor that can be programmed to physicians' specifications to monitor 24/7 intraocular pressure (IOP), detect pressure events and provide real-time IOP updates. The system delivers collected IOP data to a handheld device or tablet so physicians can evaluate treatment effectiveness in real time. Qura is led by Douglas Adams, President and Co-founder. The company raised a Series A round of undisclosed size from InFocus Capital Partners and intends to use the funds to continue to advance its system.

Total raised

$1M

Funding rounds

2

Latest round

Series A

Latest activity

Jul 2018